Sumitomo Pharma Executive and Leadership Team

Shinichiro Katayanagi, the Chair and Chief Executive Officer at Sumitomo Pharma, directs the overarching corporate strategy and long-term vision for the organization. Katayanagi oversees the integration of R&D activities across psychiatry, neurology, and oncology to ensure alignment with global market demands. By managing the executive board, the Chair and Chief Executive Officer maintains focus on the commercialization of innovative pharmaceutical products and the expansion of frontier business solutions. This leadership role involves navigating complex regulatory landscapes and fostering partnerships that enhance the company's competitive position in the international pharmaceutical sector. Shinichiro Katayanagi drives the pursuit of regenerative medicine and cell therapy, ensuring that the company addresses unmet medical needs through advanced technological applications. Ultimately, the Chair and Chief Executive Officer secures the financial health and operational excellence required to sustain growth and deliver value to patients worldwide while maintaining a strong presence in the global healthcare market.

Jennifer Henderson, the Senior Director, CSS & Toq Chief of Staff at Sumitomo Pharma, manages the operational efficiency of the corporate support services and the Toq division. Henderson coordinates cross-functional initiatives that bridge the gap between research departments and administrative execution. By streamlining internal processes, the Senior Director, CSS & Toq Chief of Staff ensures that resources remain focused on high-priority R&D projects in psychiatry and neurology. This role involves facilitating communication between the executive leadership and departmental heads to maintain organizational agility. Jennifer Henderson optimizes the deployment of cutting-edge technologies within the company's infrastructure, supporting the broader mission of addressing social issues through non-pharmaceutical healthcare solutions. Through rigorous project management and strategic oversight, the Senior Director, CSS & Toq Chief of Staff enables the organization to scale operations effectively across diverse regions, ensuring that internal workflows support the rapid development and delivery of innovative medical products to the global market.

Tara Soni, the Chief Legal Officer at Sumitomo Pharma, directs all legal affairs, compliance frameworks, and intellectual property protection strategies. Soni oversees the legal risks associated with the development of pharmaceutical products and the commercialization of new healthcare solutions. By managing complex regulatory requirements, the Chief Legal Officer ensures that all R&D activities in psychiatry, neurology, and oncology adhere to international standards. This leadership role involves providing counsel to the board on governance matters and mitigating potential liabilities in the global pharmaceutical landscape. Tara Soni architects the legal strategy for the company's frontier business, protecting innovations that address social issues beyond traditional medicine. Through proactive risk management and the enforcement of corporate policies, the Chief Legal Officer supports the company's expansion into new markets. Ultimately, Soni secures the integrity of the organization's intellectual assets, enabling the business to pursue its mission of creating innovative products while maintaining strict compliance with global health regulations.

Armin Szegedi, the Chief Medical Officer at Sumitomo Pharma, directs the clinical development and medical strategy for the company's core therapeutic areas, including psychiatry, neurology, and infectious disease. Szegedi oversees the design and execution of clinical trials, ensuring that all research meets rigorous safety and efficacy benchmarks. By collaborating with global health authorities, the Chief Medical Officer facilitates the approval and market entry of new pharmaceutical products. This leadership role involves interpreting complex clinical data to guide the R&D pipeline and support the company's commitment to regenerative medicine. Armin Szegedi drives the medical vision for the organization, ensuring that scientific advancements translate into tangible patient benefits. Through the management of medical affairs and clinical operations, the Chief Medical Officer maintains the company's reputation for scientific excellence. Ultimately, Szegedi ensures that the medical strategy aligns with the broader goal of addressing unmet needs in the global healthcare market through innovative, evidence-based solutions.

Jatin Shah, the Chief Medical Officer, Oncology at Sumitomo Pharma, directs the specialized clinical research and development programs focused exclusively on oncology. Shah oversees the advancement of cancer therapies, ensuring that the company's pipeline remains at the forefront of medical innovation. By managing clinical trial protocols and data analysis for oncology assets, the Chief Medical Officer, Oncology ensures that new treatments meet the highest standards of patient care. This leadership role involves coordinating with global research teams to accelerate the development of targeted therapies and cell-based interventions. Jatin Shah drives the strategic direction of the oncology division, ensuring that scientific breakthroughs are effectively translated into clinical practice. Through the oversight of oncology-specific medical affairs, the Chief Medical Officer, Oncology supports the company's mission to provide life-saving solutions for patients. Ultimately, Shah secures the competitive advantage of the oncology portfolio, ensuring that the organization remains a leader in the fight against cancer on a global scale.